We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sage Therapeutics Inc | NASDAQ:SAGE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.605 | 4.62% | 13.71 | 13.70 | 14.41 | 13.97 | 13.45 | 13.46 | 895,697 | 01:00:00 |
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, in New York, NY.
Steve Kanes, M.D., chief medical officer of Sage, will be a featured speaker on the panel, Overcoming Challenges in CNS Drug Development, at 11:30 a.m. EDT.
A live webcast of the panel can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190805005628/en/
Investor Contact Maren Killackey 617-949-4113 maren.killackey@sagerx.com
Media Contact Alexis Smith 617-588-3740 alexis.smith@sagerx.com
1 Year Sage Therapeutics Chart |
1 Month Sage Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions